Abstract
Enthusiasm for the use of recombinant adenoviruses in gene therapy has been tempered by the problematic immune responses that develop to the virus and virus–infected cells. Humoral immune responses to the input viral proteins generate neutralizing antibodies that thwart attempts to effectively administer the therapy more than once. Previous studies in murine models of gene therapy for cystic fibrosis (CF) have shown that the formation of adenoviral antibodies of the IgA subtype, a process that is dependent on T helper cells of the TH2 subset, contributes to a block in gene transfer that occurs following a second administration of virus. We show in this report that coadministration of interferon–γ (IFN–γ) (or interleukin–12, which activates TH1 cells to secrete IFN–γ) with the recombinant adenovirus into the airway of C57BL/6 mice diminishes the activation of TH2 cells and formation of neutralizing antibody, allowing for efficient readministration of recombinant virus. This suggests a strategy for gene therapy of CF in which administration of a short–acting immune modulator at the time of gene therapy may be sufficient to overcome the problems of humoral immunity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kay, M. et al. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. natn. Acad. Sci. U.S.A. 91, 2353–2357 (1994).
Ishibashi, S. et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. clin. Invest. 92, 883–893 (1993).
Quinn, B., Perricaudet, L.D., Tajbakhsh, S. & Mandel, J.L. Adenovirus as an expression vector in muscle cells in vivo. Proc. natn. Acad. Sci. U.S.A. 89, 2581–2584 (1992).
Rosenfeld, M.A. et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143–155 (1992).
Simon, R.H. et al. Adenovirus-mediated transfer of the CFTR gene to lung of non-human primates: Toxicity study. Hum. gene Ther. 4, 771–780 (1993).
Dai, Y. et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of both factor IX and vector antigens allows for long term expression. Proc. natn. Acad. Sci. U.S.A. (in the press).
Yang, Y. et al. Cellular immunity to viral antigens limits E1-deleted aden-oviruses for gene therapy. Proc. natn. Acad. Sci. U.S.A. 91, 4407–4411 (1994).
Yang, Y., Ertl, H.C.J. & Wilson, J.M. MHC class I restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1 deleted recombinant adenoviruses. Immunity 1, 433–442 (1994).
Yang, Y. et al. Inactivation of E2a in recombinant adenoviruses limits cellular immunity and improves the prospect for gene therapy of cystic fibrosis. Nature Genet. 7, 363–369 (1994).
Engelhardt, J.F., Litzky, L. & Wilson, J.M. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. gene Ther. 5, 1217–1229 (1994).
Smith, T.A.G. et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Gene Ther. 5, 397–402 (1993).
Yei, S., Mittereder, N., Tang, K., O'Sullivan, C. & Trapnell, B.C. Adenovirus-mediated gene transfer for cystic fibrosis: Quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1, 192–200 (1994).
Kozarsky, K.F. et al. In vivo correction of LDL receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. biol. Chem. 269, 13695–13702 (1994).
Yang, Y., Li, Q., Ertl, H.C.J. & Wilson, J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004–2015 (1995).
Yang, Y., Xiang, Z., Ertl, H.C.J. & Wilson, J.M. Upregulation of class I MHC antigens by interferon-γ is necessary for the T cell-mediated elimination of recombinant adenovirus infected hepatocytes in vivo. Proc. natn. Acad. Sci. U.S.A. (in the press).
Paul, W.E. & Seder, R.A. Lymphocyte responses and cytokines. Cell 76, 241–251 (1994).
Scott, P. IL-12: Initiation cytokine for cell-mediated immunity. Science 260, 496–497 (1993).
Manetti, R. et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. exp. Med. 177, 1199–1204 (1993).
D'Andrea, A. et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J. exp. Med. 176, 1387–1398 (1992).
Morris, S.C. et al. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J. Immun. 152, 1047–1055 (1994).
Heinzel, F.P., Schoenhaut, D.S., Rerko, R.M., Rosser, L.E. & Gately, M.K. Recombinant interleukin 12 cures mice infected with Leishmania major. J. exp. Med. 177, 1505–1509 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, Y., Trinchieri, G. & Wilson, J. Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1, 890–893 (1995). https://doi.org/10.1038/nm0995-890
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0995-890
This article is cited by
-
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα
Gene Therapy (2011)
-
Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration to lung
Gene Therapy (2006)
-
Readministration of helper-dependent adenovirus to mouse lung
Gene Therapy (2006)
-
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
Cancer Gene Therapy (2003)
-
Coexpression of p21WAF1/CIP1 in adenovirus vector transfected human primary hepatocytes prevents apoptosis resulting in improved transgene expression
Gene Therapy (2003)
